The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

KEY WORD INDEX Keyword Index (Continued) MEC ................................................. 929 mechanism of action ................ 130, 966 Mechanisms ................................. 5, 421 Mechanisms of action .......... 2225, 2402 mechlorethamine ............................ 2023 Medaka ..................... 78, 968, 992, 1777 Medical Device ....... 1, 978, 1314, 1317, 1318, 1319, 1321, 1323, 1767 medical devices .......... 1312, 1313, 1316 medicinal herbs .............................. 1118 Medium chain chlorinated paraffins ......................................... 1613 medium-term bioassay ..................... 242 Megakaryocytes ............................... 284 megalin ........................................... 1746 MEHP ........................................... 66, 70 Melamine ..................... 747, 1434, 2420 Melamine mixture ............................ 746 membrane potential ........................ 2530 membrane transporter ...................... 203 menadione ...................................... 2653 menstrual cycle .............................. 1061 menthol .................................. 574, 1409 mercapturic acids ........................... 1428 mercuric chloride ........................... 1629 mercury ................... 292, 301, 309, 610, 761, 986, 1249, 1299, 1398, 1633, 2005, 2196, 2386, 2406 Mercury-selenium interactions ...... 2590 Mesalamine .................................... 1303 Mesenchymal stem cells ......... 78, 1156, 1169 Mesoporous silica nanoparticles .... 2054 Mesothelial Cells ........................... 1509 Mesothelioma ......................... 683, 1935 Met receptor ................................... 1772 metabolic capability ....................... 1053 metabolic flux ................................ 1308 Metabolic interactions .................... 1836 metabolic profile .............................. 167 metabolic syndrome ..... 175, 1086, 1446 metabolism .... 426, 708, 884, 889, 1006, 1100, 1105, 1306, 1822, 1828, 1834, 1838, 1860, 1968, 1979, 2104, 2221, 2275, 2276, 2279, 2394, 2515 Metabolism and disposition .......... 2257, 2258 Metabolism-induced toxicology .... 2526 Metabolite profiling ....................... 2353 metabolites ..................................... 2011 Metabolome ................................... 1440 metabolomic profiling ...................... 521 metabolomics ...... 44, 72, 438, 523, 724, 735, 745, 1562, 1678, 1694, 1850, 2109 Metabolomics, Biomarker, Amino Acid, NMR, Mixture ...................... 2248 metabonomic ...................................... 45 metabonomics .................................. 523 metagenomics .................................... 45 metal ........................... 2067, 2069, 2072 Metal Genes ................................... 2168 Metal nanoparticles ........................ 1370 Metal oxide nanoparticles ..... 680, 1485, 2052 Metallothionein ....... 265, 272, 389, 412, 698, 1378, 1447, 1996 Metallothionein-3 ..................... 771, 818 Metals .............................. 208, 282, 285, 291, 296, 297, 310, 669, 915, 923, 947, 1019, 1384, 1401, 2176, 2302, 2396, 2406, 2434, 2437 Metals and Minerals ......................... 670 Metalworking ................................... 642 Metamorphosis ............................... 2379 metastasis ............................... 228, 1714 Methacholine .................................. 1921 Methamidophos .............................. 1335 Methanol ........................................ 1691 method ............................................ 2475 Method validation ........ 644, 1231, 2356 614 SOT 2011 ANNUAL MEETING methods .................................. 575, 2479 methods and models ....................... 2474 Methomyl ....................................... 1337 Methotrexate .................................... 805 methoxychlor ............. 1035, 1037, 1038 methyl hexanol ............................... 1546 methyl paraben ............................... 1823 methyl tertiary butyl ether .............. 1951 Methylarsonous Acid ....................... 233 methylation ............................ 101, 1858 methyldithiocarbamate ..................... 696 methylglyoxal ................................ 1296 methylisothiocyanate ....................... 696 methyllycaconitine ......................... 2229 Methylmercury .............. 306, 308, 1385, 1386, 1387, 1390, 1391, 1392, 1393, 1394, 1395, 1397, 1399, 1400, 1402, 1694, 1778, 2514 Methylmercury; pancreatic b-cells ............................................... 307 methylselenocysteine ..................... 1708 MFTA ............................................... 861 mice ................................ 233, 799, 1490 Micellar formulation ...................... 2046 Micro Electrode Array ................... 2510 Microarray ....... 126, 145, 395, 679, 725, 1604, 1638, 2096, 2203, 2339, 2395 Microarray Analysis ............. 2541, 2542 Microarray gene expression ........... 2402 Microarrays ...................................... 986 Microbial .......................................... 471 microbiome ........................................ 45 microbubbles .................................. 1092 microcirculation ............................... 192 microcosm ...................................... 1482 Microcystin .................................... 2436 microcystins ......................... 2390, 2435 microelectrode array ...................... 1020 microfluidic system .......................... 762 Microglia .................................. 170, 688 Microglia activation ....................... 2129 Microglial Activation ............. 171, 2130 microglial cells ............................... 1713 microgravity ..................................... 280 Microminipig ................................... 638 micronuclei ...................................... 333 Micronucleus .......................... 315, 1421 micronucleus in vitro ....................... 326 Micronucleus test ............................. 316 Micronucleus/Comet assay .............. 342 Micropatterned co-culture .............. 1094 microPET ....................................... 1661 Micropillar ..................................... 2525 microRNA ....... 383, 896, 897, 898, 900, 901, 945, 1441, 1503, 1586 micro-RNA ....................................... 151 microRNA-27a ............................... 2233 microRNAs ............................ 268, 1999 microscopy ......................................... 29 microsomal epoxide hydrolase ..... 1847, 1858 microsomal metabolism ................. 1846 microsome ........................................ 169 microtechnology .................. 2522, 2523 Microtox ........................... 503, 504, 505 Microtox assay ............................... 1313 Microtubules .................................... 382 microvascular ......................... 581, 1471 midazolam ...................................... 2598 Migration ........................................ 2061 mineral ........................................... 2443 Mineral Fibers ................................ 1267 Minimal Risk Level ....................... 1530 minipig ......... 630, 636, 786, 1248, 1921 minipigs........................ 529, 1150, 1151 miR-34a .......................................... 1429 miRNA ...... 874, 899, 1163, 1585, 1642, 2231 miRNA155 ..................................... 2321 miRNAs ......................................... 1643 mitchondrial dynamics ................... 2448 Mitochodrial ..................................... 373 Mitochondria ................... 184, 429, 432, 441, 451, 453, 493, 614, 750, 958, 961, 1087, 1304, 1608, 1653, 2045, 2125, 2528, 2529, 2530, 2580 mitochondria toxicity ..................... 1905 mitochondria-apoptosis .................... 613 Mitochondrial biogenesis ................. 748 mitochondrial differences .............. 2126 mitochondrial DNA ........................ 2448 mitochondrial Dysfunction .... 209, 1086 Mitochondrial Electrogenic Calcium Uniporter ......................... 1649 mitochondrial function ............206, 1111 mitochondrial membrane potential .......................................... 1654 mitochondrial oxidative stress ....... 1651 Mitochondrial Permeability Transition ............................. 1649, 2449 Mitochondrial toxicity .... 612, 751, 936, 1896 mitogen-activated protein kinase (MAPK) .................... 1057, 2036 Mitogen-activated protein kinases ............................................ 1998 mitophagy ...................................... 2449 mitosis ............................ 107, 357, 1095 mitotic spindle .................................. 335 Mixture ....... 18, 2262, 2305, 2307, 2313 Mixture Analysis Methods ............. 2309 mixture modeling ........................... 2303 mixture toxicology ............................. 21 mixtures ......... 16, 17, 65, 476, 503, 504, 505, 718, 1227, 1262, 1580, 1582, 1792, 1795, 2092, 2250, 2302, 2308, 2310, 2316, 2332, 2387, 2426 Mixtures, Metals .............................. 773 Mll translocations ............................. 616 MMA(III) ....................................... 1677 MMP-9 ................................. 2210, 2214 MMP9/13 ....................................... 2649 MMPs ..................................... 609, 2363 Mn toxicity ..................................... 2126 MOA .............................................. 1095 mode ................................................. 367 mode of action ........... 69, 223, 485, 858, 919, 921, 1565, 1736, 1948, 1955, 2095, 2507, 2639, 2698 model .............................................. 1538 model confidence ........................... 2690 Modeling ... 136, 725, 1736, 1810, 2291, 2689 modeling pathway response ............. 400 Mode-of-Action ..................... 916, 2350 molecular docking ............................ 140 Molecular dosimetry ...................... 1690 molecular dynamic simulation ......... 734 molecular mechanisms ................... 1774 Molecular modeling ................. 144, 162 Molecular network ............................... 9 molecular pathways analysis .......... 1600 molecular toxicology, mechanism(s) of toxicity ................ 1592 Molinate ......................................... 2088 monkey ......... 524, 661, 788, 1849, 1913 Mono-2-Ethylhexyl Phthalate ........ 1052 monoamine ....................................... 177 Monoclonal antibody ..... 797, 809, 1922 monocytes / macrophages .............. 1971 Monomethylarsonous acid ............. 1976 montmorillonite .............................. 2228 Morpholino .................................... 1741 Morris Maze ................................... 1646 Morris water maze ............... 2035, 2617 Mortality ........................................ 1567 Motilin.............................................. 786 Motor deficit .................................. 1402 Motorcycle exhaust .......................... 588 mouse ............ 133, 289, 590, 595, 1439, 1625, 2419 Mouse Laboratory Diet .................. 2362 mouse liver ..................................... 1095 Mouse Model ................. 542, 681, 1496 mouse models ................................. 1497 MPTP ............................................... 980 MRI ...................................... 1423, 2139 MRL and RfD ................................ 1811 Mrp ......................................... 414, 1079 MRP2 ............................................... 740 Mrp4 ....................................... 397, 1081 MRS ................. 1928, 2140, 2592, 2618 MTBE ........................ 1950, 1952, 2548 mtDNA ........................................... 2449 mTOR............................................... 695 MUC5AC ....................................... 2211 mucociliary clearance ...................... 552 muconic acid .................................. 1255 mucosal immunotoxicity .................... 36 multicellular tumor spheroids ........ 2659 Multicontamination ........................ 2427 multidrug resistance ....................... 2267 multifunctional proteins ................... 400 multigenerational ........................... 1747 multiple sclerosis ........................... 1508 Multiple-Path Particle Dosimetry ....................................... 2156 Multiroute ........................................ 711 MULTITEST .................................... 490 Multiwall Carbon Nanotubes ......... 1183 multi-walled carbon nanotube ........ 1186 multi-walled carbon nanotubes ... 53, 58, 59, 193, 194 municipal solid waste ..................... 1245 munitions.................................. 928, 932 muscarinic receptor ........................ 1485 mutagen .............................................. 99 Mutagenesis ............... 1404, 1417, 1419 mutagenic ....................................... 1950 mutagenic carcinogen .................... 1934 mutagenicity ............ 68, 918, 919, 1370, 1407, 1413, 1418, 1812, 2641 mutation ............... 239, 331, 1411, 1412 mutation assay .................................. 325 MWCNT ........................ 57, 1798, 1799 MXR .............................................. 2391 mycotoxin ........................ 38, 984, 2426 mycotoxins .................... 682, 832, 2153, 2425, 2427 myeloid derived suppressor cell ....... 674 Myeloperoxidase ............................ 1105 Myelosuppression .......................... 1172 myocarditis ............................. 256, 1514 myopathy ........................................ 1451 myotoxicity ...................................... 789 N, N-diethylnitrosamine .................. 247 N1E-115 Cells ................................ 1345 Na-arsenite ..................................... 1990 NAC ................................................. 753 N-acetylcysteine ............................. 1109 NAD+-sensing enzymes ................ 1703 NADPH .......................................... 2503 NADPH oxidase ................... 1302, 2130 NADPH oxidase system ................ 1307 NAFLD ................................ 1108, 2213 nano particle ................................... 1487 Nano particles ................................ 2169 nano-aerosol generation ................. 1466 nanocomposite material ................. 1798 Nanomaterial ....... 653, 851, 1480, 1488, 1717, 2082, 2083, 2085, 2156 nanomaterial characterization 1174, 1760 Nanomaterials ......... 10, 25, 1177, 1319, 1469, 1711, 1797, 2159, 2173 Nanoparticle .... 129, 192, 655, 719, 849, 1453, 1470, 1716, 2058, 2072, 2170 nanoparticle aerosol generation ..... 1455 nanoparticle exposure .................... 2504 Nanoparticle hazard studies ... 847, 1454
Keyword Index (Continued) nanoparticle size ............................. 2067 Nanoparticle toxicity .... 847, 1472, 1801 nanoparticles ................... 56, 994, 1180, 1183, 1185, 1189, 1191, 1197, 1233, 1459, 1463, 1478, 1483, 1489, 1493, 1757, 1799, 2051, 2055, 2062, 2076, 2078, 2162, 2164, 2171, 2172, 2176, 2184, 2479 nano-particles ................................. 1466 nanosilica ....................................... 2084 nanosilver ................... 1476, 1482, 1757 nano-silver ........................................ 994 nano-specific controls .................... 2158 Nanotechnology ............................... 848 Nanotoxicity .... 1455, 1486, 1488, 1757, 2073, 2171, 2172, 2182 nanotoxicity testing ........................ 2158 Nanotoxicology ................... 60, 61, 846, 849, 850, 1186, 1456, 1465, 1468, 1479, 1481, 1484, 1487, 1492, 1494, 1600, 1759, 1760, 1764, 1802, 1803, 1901, 2056, 2060, 2068, 2069, 2070, 2157, 2160, 2166, 2167, 2181, 2183 Nanotubes ...................................... 1192 Naphthalene ............ 240, 243, 580, 582, 887, 888, 1236, 1421, 1422, 1679, 1832, 1849, 1953, 1954, 1955, 1956, 1957 NAPQI ............................................. 458 nasal ................................................. 580 nasal carcinogenesis ....................... 1953 Nasal toxicity ......................... 513, 1954 NASH ............................................. 1108 NAT1 .............................................. 1863 Natriuretic peptides .......................... 202 natural killer cells ........................... 1142 natural product ............................... 2428 Natural Products ........... 479, 2220, 2222 natural sweetener ........................... 2421 nausea ............................................... 148 NCBC ............................................... 285 NCL2................................................ 801 nd-SPME ........................................ 1015 nebulizer ........................................... 584 Neonatal ............................... 2588, 2599 neonatal/prepubertal exposure ......... 618 Neonate rats ..................................... 746 Neoplastic transformation .............. 1182 neopterin ........................................ 2650 nephropathy ...................................... 250 Nephrotoxicity ........ 549, 738, 740, 743, 755, 763, 766, 1438, 1587, 1746, 2005 Nephrotoxicity, Metals ..................... 773 nerve agent ....... 2015, 2016, 2025, 2585 nervous system ............................... 1020 Network ............................................ 127 network analysis ............................. 1738 neural development ........................ 1340 Neural Differentiation ........................ 79 Neural Stem Cell ........ 1390, 2520, 2622 neurite outgrowth ............................. 870 Neurobehavior ........................ 862, 2647 neurobehavioral changes ..... 1379, 1380, 2401 neurobehavioral toxicity ........ 174, 2626 neurobehavioral toxicology ............. 897 Neurodegeneration .................. 164, 179, 182, 842, 844, 845, 1396, 1397, 1401, 2128, 2455 Neurodegenerative diseases ... 172, 1331 Neurodevelopment ............... 1772, 2144 neurodevelopmental ......................... 620 neurodevelopmental toxicity ........... 868, 2360 Neuroendocrine .............................. 1064 neurogenesis ..... 1375, 1388, 1389, 2401 Neuroimaging ................................ 2592 Neuroinflammation .................. 178, 180 neuron ............................................ 1354 neuronal .......................................... 1358 neuronal cell culture ............. 2510, 2619 Neuronal cells ................................ 1333 neuronal damage ............................ 2037 neuronal differentiation ........ 2518, 2622 Neuronal Injury .............................. 2619 Neuronal migration .............. 1386, 1387 Neuropathy Target Esterase ............. 979 neurophysiology ........ 1354, 1379, 1380, 1382, 2133 Neuroprogenitor cell ........................ 867 neuroprotectants ............................. 2014 neuroprotection ............ 161, 2049, 2585 Neurotoxic Metals ................ 1381, 2134 neurotoxicity ........... 173, 176, 178, 527, 626, 629, 1220, 1226, 1227, 1306, 1330, 1334, 1339, 1346, 1351, 1376, 1388, 1389, 1393, 1397, 1398, 1399, 1443, 1444, 1464, 1805, 1829, 2018, 2055, 2101, 2108, 2141, 2142, 2148, 2182, 2243, 2458, 2461, 2576, 2608, 2611, 2612, 2627, 2664 neurotoxicity, pesticides ................. 1207 Neurotoxicology ............. 77, 175, 1328, 1329, 1353, 1355, 1384, 2149, 2450, 2451, 2455 neurotoxin ...................................... 2039 neutrophil ......................................... 433 neutrophils ........................................ 681 nevirapine ....................................... 1505 new chemicals database ..................... 81 New Food borne diseases ............... 1211 Next Generation Sequencing ... 126, 151 NF-B ................................................ 264 Nf-kappa B ............................... 263, 431 NFkappaB .............................. 409, 1130 NF-kappaB ....................................... 257 NF-kB .................................. 2287, 2324 NF-kB/Rel ........................................ 399 NGF.................................................. 462 NHANES ................... 1241, 1261, 1693 NHP .................................................. 561 nickel ....... 236, 275, 299, 305, 813, 816, 1316, 1604 Nicotinamide .................................. 2584 Nicotine ............................................ 111 nitrated proteins ............................. 1286 nitric oxide ................... 261, 1713, 2061 Nitric Oxide Synthase .................... 1295 nitrite .............................................. 2381 Nitrogen Mustard ........................... 2026 nitrosative stress ............................... 637 nitrotyrosine ................................... 1287 nitroxide ......................................... 1407 NK cell ............................................. 693 NLRP3 ............................................... 57 N-methyl-d-aspartate ..................... 2596 N-methyl-D-aspartate (NMDA) receptor 2597 NMR ................................................ 167 NNK ................................................. 219 No Effect Level .............................. 1947 NO2 Engine emissions ................... 1290 NOAEL .......................................... 1524 noise ................................................. 160 non alcoholic fatty liver disease ..... 2582 Non Human Primate .............. 539, 1920 non human primates ......................... 562 non small cell lung cancer .............. 1361 Non-additive effects ....................... 2305 non-cancer risk assessment ............ 1962 Non-cancer toxicity ........................ 1945 non-chemical stressor ..................... 1794 non-chemical stressors ........ 1792, 1793, 1795 nonclinical safety assessment .......... 662 Nonclinical Toxicology .................. 1925 Nonclinical vehicles ......................... 790 non-coding RNA .............................. 899 Non-genotoxic .......................... 874, 875 non-genotoxic hepatocarcinogen ... 1090 nonheme iron enzymes .................... 816 non-Hodgkin lymphoma .................. 880 Nonhuman Primate ........................ 1645 non-human primate ................ 555, 1146 Non-Human Primates ..................... 1754 nonlinear ........................................ 1960 non-mammalian model species ........ 977 Non-small cell lung cancer .............. 407 nonthermal food irradiation ........... 2413 Non-Traditional Vehicle ................... 781 noradrenergic ................................... 177 norepinephrine transporter (NET) ligand 812 normalization ................................... 725 noval formulation ............................. 787 NRF1 .............................................. 2502 NRF2 ....... 179, 411, 412, 413, 414, 415, 593, 694, 1009, 1113, 1114, 1116, 1278, 1396, 1787, 1788, 1789, 1790, 2496, 2499, 2503, 2586 Nrf2-Keap1 ................... 92, 1786, 1791, 2498, 2500 NRTI ................................ 183, 209, 961 NSAID, tolfenamic acid ................... 955 NTE ................................................ 1335 N-terminal valine adducts .............. 1687 NTP Tox21 ....................................... 493 nuclear receptor ....... 225, 348, 354, 376, 2382 nuclear receptors ............ 378, 952, 1857 nucleoside reverse transcriptase inhibitors ........................................ 1275 nucleotide excision repair ....... 113, 115, 116 Oatp .............................. 548, 2247, 2390 obesity ......... 685, 760, 988, 1120, 1200, 1201, 1450, 1698, 1862, 2270, 2345 obesogens ....................................... 1201 occupational ................................... 2458 occupational asthma ................. 97, 1367 occupational exposure ......... 1180, 1220, 1267, 2139, 2156 Occupational exposure limit ................ 6 occupational health .......................... 911 occupational safety ......................... 2504 occupational standard ..................... 1529 occurrence ...................................... 1221 Ocean ............................................. 2403 ochratoxin .............................. 763, 1534 ochratoxin A ............................. 107, 320 Octopus .......................................... 2434 ocular ................................ 524, 546, 890 Ocular injury .................................. 1748 ocular irritation ........... 1001, 2550, 2569 ocular safety ......................... 1521, 1553 ocular toxicity .................................. 804 Ocular Toxicology .......................... 2568 OECD ..................................... 646, 2569 oecd validation study ..................... 2380 oedema ........................................... 1160 OEL ............................ 1803, 2296, 2538 Office Environment........................ 1225 off-target effects ............................... 853 off-target pharmacology ................... 854 OH-PCB136 ................................... 1830 OH-PCBs ......................................... 621 oil dispersants ................................. 2338 Oil Spill ........... 825, 826, 827, 828, 830, 1263, 1963, 2341, 2392 oil spills .......................................... 2340 Olfactory bulb ................................ 2595 olfactory dysfunction ..................... 2134 Olfactory Sensory Neurons ............ 1382 Olfactory toxicity ........ 538, 1379, 1380, 1382, 2133, 2319 Olfactory translocation ..................... 290 Oligonucleotide ................................ 800 Omeprazole ...................................... 361 Omic biomarkers ........ 1106, 1440, 1441 omics .......................... 1585, 1597, 1715 ‘omics ............................................. 1734 -omics technologies ........................... 42 oncogenes ......................................... 236 oncological drugs ........................... 1576 Oncology ................................ 792, 1427 Ontogenesis .................................... 2662 Ontogeny .......................................... 615 Ontology ................................ 728, 2693 oocyte maturation ........................... 1072 oocyte meiotic maturation ................ 533 oocyte morphology .......................... 533 Oocytes .......................................... 1342 OP antagonism ............................... 2048 OP Hydrolyses ............................... 2048 OP pesticides .................................. 1333 Operant behavior .................. 1402, 1886 ophthalmology ................................. 519 opioid drugs ..................................... 775 OPs exposure ................................. 1692 Optimum design of experiments ...... 478 Oral .................................................. 273 oral toxicity ............................ 787, 1547 Ordnance Environmental Program .......................................... 1544 organ toxicity ................................. 1671 organic anion transport..................... 763 organic anion transporters .............. 2268 Organic UV Filters ......................... 2179 organophosphate ....... 1326, 1676, 2049, 2120 Organophosphate Insecticide ......... 1327 Organophosphates ..... 1444, 2018, 2098, 2102, 2113 organophosphorous pesticides ...... 1330, 2097 organophosphorus .......................... 2101 organophosphorus compound ........ 2576 Organophosphorus compounds ........ 861 Organophosphorus pesticide .......... 2117 Organophosphorus pesticides ........ 1332 organoselenium .............................. 2023 organotin ................................ 695, 2393 Organotypic .................................... 2553 organotypic model............................ 466 oryza sativa japonica ...................... 2205 Oscillations ...................................... 404 osmotic stress ................................. 1276 osteoarthritis ..................................... 512 osteoblast .......................................... 276 osteoblast differentiation ................ 2217 osteoblastogenesis ............................ 352 Osteoblasts ..................................... 2369 Osteolathyrism ....................... 627, 2312 osteoporosis.............................. 277, 293 outdoor smog chamber ..................... 565 Outreach ............................... 1867, 1868 Ovarian failure ............................... 1065 Ovarian follicle depletion .............. 1026 ovarian steroidogenesis .................. 1051 Ovarian toxicology ......................... 1036 ovariectomized rat .......................... 2372 ovary .......................... 1035, 1054, 1055 oxalate crystals ................................. 758 Oxaxolidione .................................... 987 oxidant .................................... 698, 2175 oxidant stress .................................. 1290 oxidative damage ........................... 1102 Oxidative Damage ........................... 111 Oxidative DNA adducts ................. 1856 oxidative DNA damage .................. 1548 oxidative environmental pollutants .... 22 Oxidative Injury ................... 1274, 1300 oxidative lipidomics ............. 1179, 1669 oxidative phosphorylation .... 1304, 2126 SOT 2011 ANNUAL MEETING 615 KEY WORD INDEX
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIODEGRADABLE MATERIALS FOR TISSU
Page 7 and 8:
that genetic toxicology data are ge
Page 9 and 10:
well-orchestrated lung inflammation
Page 11 and 12:
scribed in the literature. We have
Page 13 and 14:
years ago). We will illustrate how
Page 15 and 16:
involved in the biodegradation proc
Page 17 and 18:
stem cells but rather a treatment i
Page 19 and 20:
additional compound showed agreemen
Page 21 and 22:
82 COMPARISON OF 3H-THYMIDINE INCOR
Page 23 and 24:
irritants. While in practice these
Page 25 and 26:
alleles are especially vulnerable t
Page 27 and 28:
109 CD4+ T CELL INTRINSIC TNF RECEP
Page 29 and 30:
118 TO STUDY THE SIGNAL TRANSDUCTIO
Page 31 and 32:
PAHs, such as dioxins, are prevalen
Page 33 and 34:
containing substituents and/or hydr
Page 35 and 36:
146 COMPUTATIONAL MODELING FOR QT P
Page 37 and 38:
suggest that the combination of too
Page 39 and 40:
164 TRANSLOCATOR PROTEIN (18 KDA) (
Page 41 and 42:
function as a metal binding protein
Page 43 and 44:
laboratory has demonstrated that NR
Page 45 and 46:
known. The aim of this study was to
Page 47 and 48:
from 5 to 28 days in duration) in e
Page 49 and 50:
positive cells, caspase-3 activatio
Page 51 and 52:
creased level in the 46 kDa preproe
Page 53 and 54:
invasiveness at concentrations repr
Page 55 and 56:
thracene (DMBA,50 μg in acetone, a
Page 57 and 58:
247 CO-CARCINOGENESIS OF N, N- DIET
Page 59 and 60:
sponds to the endosomal dsRNA that
Page 61 and 62:
ODD in both WT (maximum 177% of con
Page 63 and 64:
Lastly, using p53siRNA cells, p53 w
Page 65 and 66:
its receptor Mpl to exert its funct
Page 67 and 68:
294 LOW LEVEL OF LEAD CAN INDUCE PH
Page 69 and 70:
lunar surface presented potential h
Page 71 and 72:
lar about cellular export mechanism
Page 73 and 74:
DNA in the kidney medulla, grandula
Page 75 and 76:
5.00 and 7.50 mg/kg/day by oral gav
Page 77 and 78:
events and carcinogenesis. Here we
Page 79 and 80:
tinization of cells of the hair fol
Page 81 and 82:
358 CHARACTERIZATION OF GENOME-WIDE
Page 83 and 84:
RNAi were also performed to identif
Page 85 and 86:
376 A FUNCTIONAL CROSSTALK BETWEEN
Page 87 and 88:
UGT1A gene induction, while this re
Page 89 and 90:
tivity, specifically peroxisome pro
Page 91 and 92:
and cytotoxic effects; however, its
Page 93 and 94:
histone deacetylase that is necessa
Page 95 and 96:
ment. Paradoxically, buthionine sul
Page 97 and 98:
drug leflunomide and its major (A77
Page 99 and 100:
442 GENE EXPRESSION AND MORPHOLOGIC
Page 101 and 102:
451 INHIBITION OF THE MITOCHONDRIAL
Page 103 and 104:
460 SULFORAPHANE PREVENTS ACETAMINO
Page 105 and 106:
drophilic/lipophilic balance. Other
Page 107 and 108:
pharmacokinetic and toxicological p
Page 109 and 110:
489 USE OF ‘OMICS DATA TO IMPROVE
Page 111 and 112:
498 APPLICATION OF AGE-SPECIFIC ADJ
Page 113 and 114:
507 A DOSE VOLUME TOLERABILITY STUD
Page 115 and 116:
involved the use of an acute inflam
Page 117 and 118:
sorption in the gastrointestinal (G
Page 119 and 120:
(ABC) transporters actively transpo
Page 121 and 122:
545 BEHAVIORAL EFFECTS OF REPIN IN
Page 123 and 124:
a blood pressure phenotype that res
Page 125 and 126:
and inhalation exposure system that
Page 127 and 128:
and lethality associated with these
Page 129 and 130:
position, on vascular reactivity an
Page 131 and 132:
therefore more accurate and reprodu
Page 133 and 134:
commercial chrysotile product that
Page 135 and 136:
elative to their controls. ST-depre
Page 137 and 138:
ats. The majority of the studies fo
Page 139 and 140:
in the China Jintan Child Cohort St
Page 141 and 142:
corneum thickness, cellular epiderm
Page 143 and 144:
645 EVALUATION OF THE IN VITRO EPIS
Page 145 and 146:
654 TCDD ADSORBED ONTO NATURAL AND
Page 147 and 148:
tion revealed no test article-relat
Page 149 and 150:
671 INFLAMMATION AND TISSUE DAMAGE
Page 151 and 152:
model, ethanol was found to inhibit
Page 153 and 154:
689 ENHANCED SUPPRESSIVE FUNCTION O
Page 155 and 156:
NAC + LPS yielded different levels
Page 157 and 158:
707 LIFE-STAGE PBPK MODELS FOR MULT
Page 159 and 160:
downstream of the apical endpoint o
Page 161 and 162:
726 UPDATED ALUMINUM PHARMACOKINETI
Page 163 and 164:
global parameter sensitivity analys
Page 165 and 166:
and renal inflammation induced by 2
Page 167 and 168:
754 PLASMA, URINE, AND TISSUE CONCE
Page 169 and 170:
cently characterized transporter OA
Page 171 and 172:
exposure system was developed from
Page 173 and 174:
lood cell mass and decrease in urin
Page 175 and 176:
practical alternatives to MC in non
Page 177 and 178:
imals dosed with 167 mg/kg THU alon
Page 179 and 180:
and organ weights, clinical signs a
Page 181 and 182:
yet is induced in most bladder and
Page 183 and 184:
830 RISK ASSESSMENT OF THE SPILL: C
Page 185 and 186:
knowledgebase creation. Results are
Page 187 and 188:
852 UNDERSTANDING STRUCTURAL AND PH
Page 189 and 190:
for integrating epidemiology and an
Page 191 and 192:
motor activity, including age of th
Page 193 and 194:
y partial purification of urine (fr
Page 195 and 196:
pacity for self-renewal and may dif
Page 197 and 198:
sue. The depth of our analysis led
Page 199 and 200:
910 IMPLEMENTING CALIFORNIA’S GRE
Page 201 and 202:
concentrations in six tissues and b
Page 203 and 204:
934 THE FDA’S LIVER TOXICITY KNOW
Page 205 and 206:
943 GENOME-WIDE DNA METHYLATION DIF
Page 207 and 208:
membrane localization and subsequen
Page 209 and 210:
trols, respectively. Subtoxic and t
Page 211 and 212:
survival using both smoking regimes
Page 213 and 214:
as non-, weak, moderate, or strong
Page 215 and 216:
988 NNK-INDUCED CYTOKINE ALTERATION
Page 217 and 218:
group (one-way ANOVA, p90 % viabili
Page 219 and 220:
ered as an organ involved in xenobi
Page 221 and 222:
Transport of CPZ across the Caco-2
Page 223 and 224:
estrous cycle and sexual behavior d
Page 225 and 226:
mRNA expression levels. Collectivel
Page 227 and 228:
1043 THE EFFECTS OF ENDOCRINE DISRU
Page 229 and 230:
1052 MONO-2-ETHYLHEXYL PHTHALATE IN
Page 231 and 232:
Results: MC was variable within and
Page 233 and 234:
UtSMCs. Phosphorylation of FoxO1 wa
Page 235 and 236:
nonpregnant and pregnant diabetic m
Page 237 and 238:
1089 PFOA-INDUCED LIVER EFFECTS IN
Page 239 and 240:
events in the liver. AZD9056 was ev
Page 241 and 242:
The peppermint oil caused a concent
Page 243 and 244:
OA did not affect food consumption.
Page 245 and 246:
1126 PERSISTENT DEVELOPMENTAL ARYLH
Page 247 and 248:
1135 BACH2 BINDING TO Prdm1 AS A ME
Page 249 and 250:
The purpose of this project was to
Page 251 and 252:
one marrow. Since Chk1 is an attrac
Page 253 and 254:
1163 THE MRNA AND MIRNA PROFILE OF
Page 255 and 256:
have now compared the IC50 values b
Page 257 and 258:
1181 ELUCIDATION OF FACTORS DETERMI
Page 259 and 260:
enced by pre-exposure to cigarette
Page 261 and 262:
if abnormal PF was associated with
Page 263 and 264:
weight (P=0.016) and small for gest
Page 265 and 266:
portant cause of death, compared to
Page 267 and 268:
posure groups. However, the differe
Page 269 and 270:
Naphthalene is routinely analyzed i
Page 271 and 272:
1245 SEASONAL CHARACTERIZATION OF H
Page 273 and 274:
1255 URINARY T, T MUCONIC ACID LEVE
Page 275 and 276:
modating a reliable data evaluation
Page 277 and 278:
enzoquinone generate ROS and arylat
Page 279 and 280:
teins (e.g. C3, 4, and 5, APOB, VDB
Page 281 and 282:
1293 TRANSFORMING GROWTH FACTOR BET
Page 283 and 284:
mation was decreased to the same le
Page 285 and 286:
1312 EVALUATION OF THE SENSITIVITY
Page 287 and 288:
luted OFR and CRL. Culture media ex
Page 289 and 290:
urinary TCPy levels, blood and brai
Page 291 and 292:
activity. The dose-response curves
Page 293 and 294:
mice, each with 4 dose groups. One
Page 295 and 296:
exposure to both ATR and DACT has a
Page 297 and 298:
third tetratricopeptide repeats (TP
Page 299 and 300:
7d. 28d after TMT injury there was
Page 301 and 302:
subunits. Each cell type was treate
Page 303 and 304:
1394 COMPARATIVE EFFECTS OF METHYLM
Page 305 and 306:
1403 GENOTOXICITY AND PRE-NEOPLASTI
Page 307 and 308:
vated only in high-dose-treated ani
Page 309 and 310:
1421 DOSE-RESPONSE OF NAPHTHALENE-I
Page 311 and 312:
cisplatin; 1.2-, 1.9- and 2.9-fold
Page 313 and 314:
Day 11 and started to recover on Da
Page 315 and 316:
1448 DEVELOPMENT OF A METHOD FOR QU
Page 317 and 318:
1457 GLOBAL GENE PROFILING REVEALS
Page 319 and 320:
cluding mouse and human macrophage,
Page 321 and 322:
model of lung inflammation and host
Page 323 and 324:
1484 NANOTOXICOLOGY AND NANOHEALTH
Page 325 and 326:
throughput in vitro approach was us
Page 327 and 328:
1502 IMMUNOLOGICAL ASPECTS OF AN AN
Page 329 and 330:
(CIA) and the Streptococcal cell wa
Page 331 and 332:
sitizers were 100% concordant among
Page 333 and 334:
1530 MINIMAL RISK LEVELS FOR STYREN
Page 335 and 336:
ical groups in the field of regulat
Page 337 and 338:
vitro with this potentially insect-
Page 339 and 340:
their performance on toxicological
Page 341 and 342:
need for a better understanding of
Page 343 and 344:
1577 AN IN VITRO MODEL SYSTEM FOR A
Page 345 and 346:
gene expression post-transcriptiona
Page 347 and 348:
1595 GENE EXPRESSION PROFILE OF RAT
Page 349 and 350:
to confirm a hepatotoxic property o
Page 351 and 352:
1613 AN INVESTIGATION OF THE CLEARA
Page 353 and 354:
its nuclear translocation was reduc
Page 355 and 356:
were collected from TK animals at d
Page 357 and 358:
egulated targets were selected for
Page 359 and 360:
U/L after tetracycline. Minocycline
Page 361 and 362:
peri-pubertal FasL-/- mice show a d
Page 363 and 364:
showed similar levels of apoptosis
Page 365 and 366:
1676 TWO BIOMARKERS FOR EVALUATION
Page 367 and 368:
motifs selected. This system was ap
Page 369 and 370:
1693 VOC SERUM LEVELS IN THE GENERA
Page 371 and 372:
1702 DOES THE CLOCK MAKE THE POISON
Page 373 and 374:
those with high nickel content are
Page 375 and 376:
isk assessment. However, unique cha
Page 377 and 378:
model of APAP metabolism and glutat
Page 379 and 380:
logically & morphologically similar
Page 381 and 382:
posure, blood chemistry was analyze
Page 383 and 384:
elated to oxidative stress by measu
Page 385 and 386:
ostasis), but work is needed to tra
Page 387 and 388:
tokine products during carcinogenes
Page 389 and 390:
ways as chemical stressors and, the
Page 391 and 392:
toxicity of nanomaterials relates s
Page 393 and 394:
1815 MEASURING COMPOUND SELECTIVITY
Page 395 and 396:
1825 EFFECTS OF METABOLISM BY INTES
Page 397 and 398:
cyanoacetic acid increased 2-3 fold
Page 399 and 400:
1845 IS THE PROMISCUITY OF THE ARYL
Page 401 and 402:
crorarray analysis. RT-PCR results
Page 403 and 404:
are a family of phase-II biotransfo
Page 405 and 406:
ous labs. As a result of positive s
Page 407 and 408:
down the doses may produce more tox
Page 409 and 410:
spectively. Below 100 mg/l of gemfi
Page 411 and 412:
1900 GENERATION OF PRECISION CUT LI
Page 413 and 414:
iomarkers or observation of lesions
Page 415 and 416:
creased reticulocytes and lymphocyt
Page 417 and 418:
statistically significant interacti
Page 419 and 420:
monize sample preparation and analy
Page 421 and 422:
NPC and sinonasal cancer in neighbo
Page 423 and 424:
showed incidences of lung and nasal
Page 425 and 426:
utylbenzenes, exhibited most simila
Page 427 and 428:
1975 DIFFERENTIAL MODULATION OF CYP
Page 429 and 430:
organic As to MMA(V) and a lower ca
Page 431 and 432:
ole in invasion and metastasis of c
Page 433 and 434:
3T3-L1 cells to low-levels of arsen
Page 435 and 436:
2011 IDENTIFICATION OF A NOVEL VX M
Page 437 and 438:
This work was supported by Cooperat
Page 439 and 440:
2029 EFFICACY OF ENDOTRACHEAL ADMIN
Page 441 and 442:
Diazepam injections and its combina
Page 443 and 444:
2047 ESTERASE ACTIVITIES AND HEMOST
Page 445 and 446:
nanoparticle-induced toxicity progr
Page 447 and 448:
house, were iv infused into rats ov
Page 449 and 450:
een explored. This study investigat
Page 451 and 452:
croscopic analysis revealed that on
Page 453 and 454:
egg yolk collected from turtles inh
Page 455 and 456:
consistency of results in both expe
Page 457 and 458:
2111 CYTOCHROME P450 3A5 GENOTYPE I
Page 459 and 460:
esidues of organophosphates or thei
Page 461 and 462:
manganism. Recent work from our lab
Page 463 and 464:
Aβ1-40 in CSF and hippocampus in P
Page 465 and 466:
2147 CATALASE MANIPULATIONS MODIFY
Page 467 and 468:
ation based on real-world exposure
Page 469 and 470:
NPs. Aggregation of citrate-stabili
Page 471 and 472:
2175 THE ROLE OF SURFACE CHEMISTRY
Page 473 and 474:
seen rapid uptake in biological ima
Page 475 and 476:
effect on uterine weight or vaginal
Page 477 and 478:
dicating widespread exposure. While
Page 479 and 480:
components into the liver parenchym
Page 481 and 482:
2223 ISOLATION AND DETECTION OF RIC
Page 483 and 484:
stored (-20 celsius degree). The co
Page 485 and 486:
2241 DDA, A BIOMARKER FOR ENVIRONME
Page 487 and 488:
2249 INTERACTION BETWEEN DIETARY SE
Page 489 and 490:
2258 PHARMACOKINETICS, EXCRETION BA
Page 491 and 492:
2267 SENSITIVE AND SPECIFIC FLUORES
Page 493 and 494:
2276 METABOLISM AND DISPOSITION OF
Page 495 and 496:
ment of hypertension in companion a
Page 497 and 498:
for the propyl series can be used f
Page 499 and 500:
2304 IN VITRO EXPOSURE AND EVALUATI
Page 501 and 502:
2313 THE SYNERGISTIC EFFECT OF SODI
Page 503 and 504:
genes that play a crucial role in M
Page 505 and 506:
2330 THE ROLE OF TRANSFORMING GROWT
Page 507 and 508:
ined following up to 96 h continuou
Page 509 and 510:
effect doses obtained with the rat
Page 511 and 512:
diated transcriptional response of
Page 513 and 514:
docrine disruptor activities of EDC
Page 515 and 516:
individuals. Week 6 results were qu
Page 517 and 518:
functionality of photosystem II and
Page 519 and 520:
wild mice (Mus musculus) from areas
Page 521 and 522:
2406 TOXICITY AND BIOACCUMULATION O
Page 523 and 524:
Isocitric acid is the acid in the h
Page 525 and 526:
2425 EFFECTS OF FUMONISINS IN ETHAN
Page 527 and 528:
centration(μg/g) were: 5.1-95.3; 2
Page 529 and 530:
2445 AUTOPHAGY IN DEVELOPMENT: A LI
Page 531 and 532:
sures to inhaled Mn in dust. Nevert
Page 533 and 534:
2466 CRITICAL EVALUATION OF ANIMAL
Page 535 and 536:
elationships predict that resting r
Page 537 and 538:
2489 COMPARATIVE TOXICITY OF BIODIE
Page 539 and 540:
2497 TRANSCRIPTIONAL REGULATION OF
Page 541 and 542:
2506 TOXICOLOGICAL CONSIDERATIONS O
Page 543 and 544:
launched with the aim of developing
Page 545 and 546:
forms mRNA expression levels were a
Page 547 and 548:
2534 CUTANEOUS WOUND HEALING IN THE
Page 549 and 550:
wells (0, 1, 5, 10, 25, 50, 100, an
Page 551 and 552:
2553 AN ORGANOTYPIC MICROLIVER PLAT
Page 553 and 554:
serum-free media. At 24 hrs, the gr
Page 555 and 556:
2572 INCREASED ARSENIC BIOACCESSIBI
Page 557 and 558:
nology to develop improved methods.
Page 559 and 560:
tuna, swordfish, or mako shark (3.5
Page 561 and 562:
nificantly reduce circulating thyro
Page 563 and 564:
grouped into 9 observation periods
Page 565 and 566:
histopathological or biochemical ev
Page 567 and 568: exhibited a hyperactive phenotype,
Page 569 and 570: the search of effective drugs for e
Page 571 and 572: 2644 COVALENT BINDING OF 14 C 2-MET
Page 573 and 574: aries targeting all transcription f
Page 575 and 576: (p 9 weeks) and CSC phenotype acqui
Page 577 and 578: 2673 IMMUNE-MEDIATED VASCULAR INJUR
Page 579 and 580: for risk identification and charact
Page 581 and 582: to control toxicant delivery in tob
Page 583 and 584: Author Index (Continued) The numera
Page 611 and 612: Keyword Index (Continued) Arsenite
Page 613 and 614: Keyword Index (Continued) Covalent
Page 615 and 616: Keyword Index (Continued) flow cyto
Page 617: Keyword Index (Continued) innate im
Page 621 and 622: Keyword Index (Continued) preservat
Page 623 and 624: Keyword Index (Continued) Thrombocy
Page 625 and 626: Toxicological Sciences The Official
show all

The Toxicologist - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?